Skip to content
2000
Volume 22, Issue 11
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Cancer therapy is based on the killing of cancer cells using various therapeutic agents, such as radiation, chemotherapy or targeted therapy drugs, and immunotherapy. Cancer cells may undergo apoptosis, mitotic catastrophe, necrosis, autophagy, mitophagy, senescence, etc., depending on the therapeutic modality and nature of cancer cells. Mutations in some critical genes, such as p53 and Phosphatase and Tensin Homolog (PTEN) tumor suppressor genes, are associated with immune escape of cancer cells and tumor progression. Furthermore, the overexpression of some genes. such as phosphatidylinositol-3-kinase (PI3K), Nuclear Factor of Kappa B (NF-ΚB), cyclooxygenase-2 (COX-2) and mammalian Target of Rapamycin (mTOR), is associated with the resistance of cancer cells to various types of cell death. Melatonin is known as a circadian regulator hormone that has several anti-cancer properties. It has the ability to activate tumor suppressor genes and attenuate the expression of survival genes in cancer cells. Modulation of cell death or survival genes that have been disrupted or overexpressed in cancer cells can improve cancer therapy. In this review, we explain the potential of melatonin in regulating various mechanisms of cancer cell death.

Loading

Article metrics loading...

/content/journals/acamc/10.2174/1871520621999211108090712
2022-07-01
2025-03-15
Loading full text...

Full text loading...

/content/journals/acamc/10.2174/1871520621999211108090712
Loading

  • Article Type:
    Review Article
Keyword(s): apoptosis; autophagy; cancer; Melatonin; mitotic catastrophe; senescence
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test